Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x100px
Document › Details

Freshfields Brukhaus Deringer. (9/17/20). "Press Release: Freshfields Advises Univercells in Two Successive Equity Raising and Financing".

Organisations Organisation Freshfields Bruckhaus Deringer LLP, Office Brussels
  Group Freshfields (Group)
  Organisation 2 Univercells S.A.
  Group Univercells (Group)
Products Product legal services
  Product 2 biologics manufacturing technology
  Index term 2 Univercells–SEVERAL: investment, 202009 financing round Series C first closing €50m led by Adjuvant Capital + SFPI + SRIW
Person Person Janssens, Deborah (Freshfields 202009 Partner at Brussels Office)
     


Freshfields Brukhaus Deringer ('Freshfields') has advised Univercells in the second largest equity raising in the life sciences sector in Belgium this year and on an equity financing by Gamma Biosciences, a KKR fund, in its subsidiary Univercells Technologies.

Univercells is a Belgian company active in the medical and biomedical industry with a view to delivering novel biomanufacturing platforms and solutions.

The latest investment is a Series-C financing by which existing shareholders and new investors have agreed to invest EUR 50 million. This investment will contribute to finance Univercells' vaccines (including Covid-19 related projects), biosimilars and contract development and manufacturing business units.

Earlier in the year, we advised Univercells on a joint venture and equity investment by Gamma Biosciences, a KKR fund, in Univercells Technologies to further accelerate the development of the manufacturing technologies business of Univercells.

These deals constitute a significant milestone for this promising Belgian company, which continues to attract large international investors, such as the Bill & Melinda Gates Foundation, private equity fund KKR, and Belgian public investors, such as SFPI-FPIM and SRIW. This second investment round places Univercells at the top of the chart of Belgian life sciences companies being funded by high profile investors.

The corporate team in Brussels was led by partner Deborah Janssens and associate Elliott Fosséprez, with the support from associates Alicia Harte and Coline Minguet.

   
Record changed: 2023-06-05

Advertisement

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x300px




» top